The Global Degenerative Disc Disease Treatment Market size is expected to reach $442.5 Billion by 2031, rising at a market growth of 5.3% CAGR during the forecast period.
Many countries in the Asia-Pacific region have made significant investments in healthcare infrastructure, expanding access to specialized medical facilities, spine centers, and rehabilitation clinics equipped with advanced diagnostic technologies and treatment modalities for managing DDD. Consequently, the Asia Pacific region would acquire nearly 25% of the total market share by 2031.
Increased awareness leads to earlier recognition of symptoms and encourages individuals to seek medical advice sooner. In addition, greater awareness often spurs investments in diagnostic technologies, such as MRI scans, CT scans, and other imaging modalities. Thus, the rising awareness and early diagnosis of spinal disorders drive the market's growth. Additionally, Higher healthcare spending allows healthcare systems to invest in advanced treatment options for degenerative disc disease. Increased funding enables the expansion and modernization of healthcare facilities, including specialized centers for spinal health.
However, the high cost of advanced treatments such as minimally invasive surgeries, biologic therapies, and regenerative medicine can be prohibitive for many patients. Many insurance providers may not cover the full cost of advanced DDD treatments or may have stringent criteria for coverage approval. Hence, high treatment costs are impeding the growth of the market.
Moreover, Restrictions on international and domestic logistics disrupted the supply chain for medical devices and pharmaceuticals used in DDD treatments. This led to shortages and delayed availability of necessary treatment options. Economic uncertainties caused by the pandemic led to financial constraints for healthcare providers and patients. Thus, the COVID-19 pandemic had a negative impact on the market.
Many countries in the Asia-Pacific region have made significant investments in healthcare infrastructure, expanding access to specialized medical facilities, spine centers, and rehabilitation clinics equipped with advanced diagnostic technologies and treatment modalities for managing DDD. Consequently, the Asia Pacific region would acquire nearly 25% of the total market share by 2031.
Increased awareness leads to earlier recognition of symptoms and encourages individuals to seek medical advice sooner. In addition, greater awareness often spurs investments in diagnostic technologies, such as MRI scans, CT scans, and other imaging modalities. Thus, the rising awareness and early diagnosis of spinal disorders drive the market's growth. Additionally, Higher healthcare spending allows healthcare systems to invest in advanced treatment options for degenerative disc disease. Increased funding enables the expansion and modernization of healthcare facilities, including specialized centers for spinal health.
However, the high cost of advanced treatments such as minimally invasive surgeries, biologic therapies, and regenerative medicine can be prohibitive for many patients. Many insurance providers may not cover the full cost of advanced DDD treatments or may have stringent criteria for coverage approval. Hence, high treatment costs are impeding the growth of the market.
Moreover, Restrictions on international and domestic logistics disrupted the supply chain for medical devices and pharmaceuticals used in DDD treatments. This led to shortages and delayed availability of necessary treatment options. Economic uncertainties caused by the pandemic led to financial constraints for healthcare providers and patients. Thus, the COVID-19 pandemic had a negative impact on the market.
Driving and Restraining Factors
Drivers- Rising awareness and early diagnosis of spinal disorders
- Increasing healthcare expenditure globally
- Rising incidence of spinal disorders globally
- Rising awareness and early diagnosis of spinal disorders
- Increasing healthcare expenditure globally
- Rising incidence of spinal disorders globally
- Growing demand for minimally invasive surgical procedures
- Aging population increasing the prevalence of degenerative diseases
- Complexity of diagnosis and management
- Impact of comorbidities and multimorbidity
Route of Administration Outlook
By route of administration, the market is segmented into injectable and oral. The injectable segment procured a 35% revenue share in the degenerative disc disease treatment market in 2023. Injectables allow for direct delivery of medications to specific sites within the spine affected by DDD.Drugs Outlook
Based on drugs, the degenerative is divided into acetaminophen, NSAIDs (non-steroidal anti-inflammatory drugs), muscle relaxants, and steroids. The muscle relaxants segment attained a 22% revenue share in the degenerative disc disease treatment market in 2023. Muscle relaxants are effective in relieving muscle spasms, which are common symptoms of DDD.End Use Outlook
Based on end use, the market is categorized into hospitals, clinics, and others. The clinics segment witnessed 34% growth rate in the degenerative disc disease treatment market in 2023. Clinics provide accessible healthcare services in community settings, making it easier for patients with DDD to seek timely medical attention and treatment close to their homes.Treatment Type Outlook
On the basis of treatment type, the market is segmented into occupational therapy, physical therapy, special exercises, medications, and weight loss surgery. In 2023, the occupational therapy segment attained 22% revenue share in the degenerative disc disease treatment market. Occupational therapy focuses on enhancing a person's ability to perform activities of daily living (ADLs) independently and safely.Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 40% revenue share in the market in 2023. In North America, sedentary lifestyles are common, marked by extended periods of sitting, inadequate physical activity, and poor posture.List of Key Companies Profiled
- Medtronic PLC
- AstraZeneca PLC
- Pfizer, Inc.
- Novartis AG
- Eli Lilly And Company
- Spine Wave Inc.
- Braun Melsungen AG (Aesculap, Inc.)
- DiscGenics, Inc.
- Spine BioPharma Inc.
- Stryker Corporation
Market Report Segmentation
By Route of Administration- Oral
- Injectable
- NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- Acetaminophen
- Muscle Relaxants
- Steroids
- Hospitals
- Clinics
- Others
- Physical Therapy
- Occupational Therapy
- Special Exercises
- Weight Loss Surgery
- Medications
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Global Degenerative Disc Disease Treatment Market by Route of Administration
Chapter 5. Global Degenerative Disc Disease Treatment Market by Drugs
Chapter 6. Global Degenerative Disc Disease Treatment Market by End Use
Chapter 7. Global Degenerative Disc Disease Treatment Market by Treatment Type
Chapter 8. Global Degenerative Disc Disease Treatment Market by Region
Chapter 9. Company Profiles
Companies Mentioned
- Medtronic PLC
- AstraZeneca PLC
- Pfizer, Inc.
- Novartis AG
- Eli Lilly And Company
- Spine Wave Inc.
- B. Braun Melsungen AG (Aesculap, Inc.)
- DiscGenics, Inc.
- Spine BioPharma Inc.
- Stryker Corporation
Methodology
LOADING...